Pay in 4 interest-free payments of $15.50 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
which circumvents the selectivity and pharmacologic liabilities of hydroxamates
the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and inflammatory and autoimmune diseases
It modulates the coupling of Smo with its downstream effector by interacting with the Smo heptahelical domain (KD = 59 nM)
6-dihydro-4H-pyridin-2-yl]pyridine dihydrochloride
Su-11274 - CAS# 658084-23-2 Catalog No.:M6418-10 which circumvents the selectivity andSu 11274, CAS No. 658084 23 2, is a selective Met tyrosine kinase inhibitor with IC50 of 10 nM. Su 11274 increases tumorigenicity and enriched for melanoma initiating cells by bioenergetic modulation. Su 11274 suppresses proliferation and motility of pancreatic cancer cells. Su 11274 enhances the response of the prostate cancer cell line DU145 to ionizing radiation. Su 11274 exhibits a selective inhibition pattern toward different receptor mutated
US$ 742.00
US$ 212.50
US$ 195.00
US$ 125.00
US$ 466.00
US$ 2497.50
US$ 1497.50
US$ 447.00
US$ 935.00
US$ 405.00
US$ 454.00
US$ 2047.50
US$ 504.50
US$ 510.50
US$ 169.00
US$ 95.00
US$ 639.00
US$ 35.00